Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares traded down 3.5% during mid-day trading on Friday . The company traded as low as $15.37 and last traded at $15.67, with a volume of 101,414 shares trading hands. The stock had previously closed at $16.24.

A number of research analysts recently issued reports on the stock. Noble Financial reissued a “buy” rating and issued a $25.00 price objective on shares of Adamas Pharmaceuticals in a research note on Friday. Mizuho raised shares of Adamas Pharmaceuticals from a “neutral” rating to a “buy” rating in a research note on Monday, June 13th. Cowen and Company reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Thursday, May 12th. JMP Securities reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research note on Wednesday, June 15th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $44.00 price objective on shares of Adamas Pharmaceuticals in a research note on Tuesday, June 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $33.60.

The firm has a 50 day moving average price of $16.12 and a 200-day moving average price of $16.55. The company’s market cap is $335.43 million.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.11. Equities analysts expect that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Russell Frank Co raised its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 119.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 83,773 shares of the specialty pharmaceutical company’s stock after buying an additional 45,652 shares during the period. Russell Frank Co owned approximately 0.45% of Adamas Pharmaceuticals worth $2,395,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.